Literature DB >> 21486961

Enhancement of amoxicillin resistance after unsuccessful Helicobacter pylori eradication.

Toshihiro Nishizawa1, Hidekazu Suzuki, Hitoshi Tsugawa, Hiroe Muraoka, Juntaro Matsuzaki, Kenro Hirata, Fumiaki Ikeda, Masahiko Takahashi, Toshifumi Hibi.   

Abstract

A high rate of resistance (49.5 to 72.7%) to amoxicillin (AMX) was observed in Helicobacter pylori after two or three unsuccessful eradication attempts. Unsuccessful eradication regimens significantly increase resistance to not only clarithromycin (CLR) and metronidazole (MNZ) but also AMX.

Entities:  

Mesh：

Substances：

Year:  2011        PMID： 21486961      PMCID： PMC3101459          DOI： 10.1128/AAC.00188-11

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  11 in total

1.  Sitafloxacin and garenoxacin may overcome the antibiotic resistance of Helicobacter pylori with gyrA mutation.

Authors:  Hidekazu Suzuki; Toshihiro Nishizawa; Hiroe Muraoka; Toshifumi Hibi
Journal:  Antimicrob Agents Chemother       Date:  2009-02-02       Impact factor: 5.191

Review 2.  Helicobacter pylori eradication therapy.

Authors:  Hidekazu Suzuki; Toshihiro Nishizawa; Toshifumi Hibi
Journal:  Future Microbiol       Date:  2010-04       Impact factor: 3.165

3.  Gatifloxacin resistance and mutations in gyra after unsuccessful Helicobacter pylori eradication in Japan.

Authors:  Toshihiro Nishizawa; Hidekazu Suzuki; Kumiko Kurabayashi; Tatsuhiro Masaoka; Hiroe Muraoka; Mikiji Mori; Eisuke Iwasaki; Intetsu Kobayashi; Toshifumi Hibi
Journal:  Antimicrob Agents Chemother       Date:  2006-04       Impact factor: 5.191

4.  Contribution of efflux pumps to clarithromycin resistance in Helicobacter pylori.

Authors:  Kenro Hirata; Hidekazu Suzuki; Toshihiro Nishizawa; Hitoshi Tsugawa; Hiroe Muraoka; Yoshimasa Saito; Juntaro Matsuzaki; Toshifumi Hibi
Journal:  J Gastroenterol Hepatol       Date:  2010-05       Impact factor: 4.029

5.  Enhanced bacterial efflux system is the first step to the development of metronidazole resistance in Helicobacter pylori.

Authors:  Hitoshi Tsugawa; Hidekazu Suzuki; Hiroe Muraoka; Fumiaki Ikeda; Kenro Hirata; Juntaro Matsuzaki; Yoshimasa Saito; Toshifumi Hibi
Journal:  Biochem Biophys Res Commun       Date:  2010-12-11       Impact factor: 3.575

6.  Rapid detection of point mutations conferring resistance to fluoroquinolone in gyrA of Helicobacter pylori by allele-specific PCR.

Authors:  Toshihiro Nishizawa; Hidekazu Suzuki; Ayako Umezawa; Hiroe Muraoka; Eisuke Iwasaki; Tatsuhiro Masaoka; Intetsu Kobayashi; Toshifumi Hibi
Journal:  J Clin Microbiol       Date:  2006-11-22       Impact factor: 5.948

7.  Second-line treatment of Helicobacter pylori infection after dilution agar methods and PCR-RFLP analysis.

Authors:  T Masaoka; H K SuzukiKurabayashi; A G Kamiya; H Ishii
Journal:  Aliment Pharmacol Ther       Date:  2004-07       Impact factor: 8.171

8.  Mutations in penicillin-binding proteins 1, 2 and 3 are responsible for amoxicillin resistance in Helicobacter pylori.

Authors:  Emiko Rimbara; Norihisa Noguchi; Takashi Kawai; Masanori Sasatsu
Journal:  J Antimicrob Chemother       Date:  2008-02-14       Impact factor: 5.790

9.  A new eradication resistance index as a predictor of metronidazole-containing second-line treatment of Helicobacter pylori.

Authors:  Toshihiro Nishizawa; Hidekazu Suzuki; Tatsuhiro Masaoka; Eisuke Iwasaki; Toshifumi Hibi
Journal:  Digestion       Date:  2007-12-21       Impact factor: 3.216

10.  Gatifloxacin-based triple therapy as a third-line regimen for Helicobacter pylori eradication.

Authors:  Toshihiro Nishizawa; Hidekazu Suzuki; Izumi Nakagawa; Eisuke Iwasaki; Tatsuhiro Masaoka; Toshifumi Hibi
Journal:  J Gastroenterol Hepatol       Date:  2008-12       Impact factor: 4.029
View more
  16 in total

1.  In vitro and in vivo activities of HPi1, a selective antimicrobial against Helicobacter pylori.

Authors:  Ekaterina Gavrish; Binu Shrestha; Chao Chen; Ida Lister; E Jeffrey North; Lei Yang; Richard E Lee; Angel Han; Bronwyn Williams; David Charnuska; Ken Coleman; Kim Lewis; Michael D LaFleur
Journal:  Antimicrob Agents Chemother       Date:  2014-03-31       Impact factor: 5.191

2.  Reply to letter to the editor: "The dosage of rifabutin in H. pylori eradication regimen should be appropriately determined in each area of the world".

Authors:  Hideki Mori; Hidekazu Suzuki
Journal:  United European Gastroenterol J       Date:  2016-05-27       Impact factor: 4.623

3.  Dual therapy for third-line Helicobacter pylori eradication and urea breath test prediction.

Authors:  Toshihiro Nishizawa; Hidekazu Suzuki; Takama Maekawa; Naohiko Harada; Tatsuya Toyokawa; Toshio Kuwai; Masanori Ohara; Takahiro Suzuki; Masahiro Kawanishi; Kenji Noguchi; Toshiyuki Yoshio; Shinji Katsushima; Hideo Tsuruta; Eiji Masuda; Munehiro Tanaka; Shunsuke Katayama; Norio Kawamura; Yuko Nishizawa; Toshifumi Hibi; Masahiko Takahashi
Journal:  World J Gastroenterol       Date:  2012-06-07       Impact factor: 5.742

4.  Helicobacter pylori resistance to rifabutin in the last 7 years.

Authors:  Toshihiro Nishizawa; Hidekazu Suzuki; Juntaro Matsuzaki; Hiroe Muraoka; Hitoshi Tsugawa; Kenro Hirata; Toshifumi Hibi
Journal:  Antimicrob Agents Chemother       Date:  2011-09-06       Impact factor: 5.191

5.  Whole-Genome Sequencing and Comparative Genomics of Three Helicobacter pylori Strains Isolated from the Stomach of a Patient with Adenocarcinoma.

Authors:  Montserrat Palau; Núria Piqué; M José Ramírez-Lázaro; Sergio Lario; Xavier Calvet; David Miñana-Galbis
Journal:  Pathogens       Date:  2021-03-12

6.  Analysis of clinical isolates of Helicobacter pylori in Pakistan reveals high degrees of pathogenicity and high frequencies of antibiotic resistance.

Authors:  Faisal Rasheed; Barry James Campbell; Hanafiah Alfizah; Andrea Varro; Rabaab Zahra; Yoshio Yamaoka; David Mark Pritchard
Journal:  Helicobacter       Date:  2014-05-14       Impact factor: 5.753

Review 7.  Helicobacter pylori infection and antibiotic resistance - from biology to clinical implications.

Authors:  Evariste Tshibangu-Kabamba; Yoshio Yamaoka
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2021-05-17       Impact factor: 46.802

8.  Genetic and Transcriptomic Variations for Amoxicillin Resistance in Helicobacter pylori under Cryopreservation.

Authors:  Xiurui Han; Yiyao Zhang; Lihua He; Ruyue Fan; Lu Sun; Dongjie Fan; Yanan Gong; Xiaoli Chen; Yuanhai You; Fei Zhao; Maojun Zhang; Jianzhong Zhang
Journal:  Pathogens       Date:  2021-05-30

9.  Proton pump inhibitor-amoxicillin-clarithromycin versus proton pump inhibitor-amoxicillin-metronidazole as first-line Helicobacter pylori eradication therapy.

Authors:  Toshihiro Nishizawa; Hidekazu Suzuki; Masayuki Suzuki; Masahiko Takahashi; Toshifumi Hibi
Journal:  J Clin Biochem Nutr       Date:  2012-03-30       Impact factor: 3.114

10.  Changes in Antibiotic Susceptibility of Helicobacter pylori in the Course of Eight Years in the Zaanstreek Region in The Netherlands.

Authors:  R J L F Loffeld; B F M Werdmuller
Journal:  Gastroenterol Res Pract       Date:  2013-03-12       Impact factor: 2.260
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.